Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201669 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00201669: Completed Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT00201669 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00201669, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will determine the efficacy of clofarabine as measured by response rate in patients with aggressive non-Hodgkin's lymphoma
Interventions
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00201669 record still lists
NCT00201669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Clofarabine is the first listed.
NCT00201669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00201669 about?
NCT00201669 is a clinical study titled "A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma". This study will determine the efficacy of clofarabine as measured by response rate in patients with aggressive non-Hodgkin's lymphoma
What is the current status of trial NCT00201669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2004-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00201669?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00201669?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00201669's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia